Full-Time

Program Manager

Embedded Software & Hardware

Tandem Diabetes Care

Tandem Diabetes Care

1,001-5,000 employees

Develops subcutaneous insulin pumps and software

Compensation Overview

$120k - $150k/yr

+ Bonus

No H1B Sponsorship

Del Mar, CA, USA

Hybrid

Hybrid role requiring 1-2 days on-site per week in Del Mar, CA.

Category
Business & Strategy (1)
Required Skills
Agile
SCRUM
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Ability to work in a matrixed environment, establishing a sphere of influence with both the functional and vertical organizations.
  • Ability to drive cultural change through implementation of best practices in project teams.
  • Ability to communicate and influence up in order to manage project scope and resources.
  • Ability to keep project teams focused, motivated, creatively work to keep the projects on schedule.
  • Proficient in the use of Project Management Tools for planning, work breakdown, scheduling, task estimation, and collaboration.
  • Advanced Microsoft Office skills: Excel (Forms, Formulas, Functions, Pivot Tables, Graphs), PowerPoint (Graphics & Animation), MS-Project (Resource loading, tracking).
  • ECO writing/review.
  • Ability to communicate effectively both orally and in writing and to establish and maintain cooperative working relationships with people contacted in the course of performing assigned duties including Company management and outside business associates.
  • Ability to interact with executive management on a regular basis.
  • Ability to represent Tandem at professional and business functions in a competent manner.
  • Excellent advocacy and persuasive skills.
  • Ability to maintain confidentiality.
  • Ability to organize and prioritize workflow and to meet established timeframes.
  • Ability to maintain updated knowledge of products, procedures and of changes within the medical device industry.
  • Ability to provide feedback and suggestions for improvement on the Product Development Process.
  • Ability to assess a problem quickly and determine to what level it should be elevated, directing staff/customers to the correct person(s).
  • Knowledge of agile/scrum development methodology.
  • Strong understanding of engineering principles, theories, and concepts.
Responsibilities
  • Provides project management expertise and leadership to a multi-functional core team from Concept through Commercialization following Tandem’s standard process for product development and/or Design change; ensures implementation and compliance to Design Control procedures and improvements of systems, procedures, and documentation.
  • Plans and directs all aspects of software/systems projects/programs. Establishes project plans and objectives, develops project cost analysis, establishes, and manages the project schedule and budget, manages resources, tracks progress, and provides updates to management and external partners.
  • Works closely with the Program Office, Project Managers, and functional heads to resolve resource allocation issues, conflicts, and priorities and to ensure projects are staffed appropriately, completed on time, and within budget constraints.
  • Ensures efficient transfer of product from R&D to manufacturing and external marketing.
  • Leads/participates in process improvement initiatives related to product development, resource management and allocation, design controls, and other areas that impact cycle time, efficiencies, and compliance in medical device product development.
  • Communicates and presents regular and timely project status updates to various levels of the organization including the executive management team and external partners.
  • As necessary, performs other duties as required to support the PMO.
Desired Qualifications
  • Bachelor’s degree in engineering or a related field; or a combination of education and applicable experience.
  • Certificate in Project Management (PMP) is desired. Alternatively, should be willing to pursue professional certification in the future.
  • Scrum Certification a plus.
  • 4 years’ directly related experience in managing projects in FDA-regulated and ISO 14971 certified industry.
  • 4 years’ experience in the medical device industry and compliance to internal Quality Systems.
  • Experience in managing projects from inception to post-market sustaining using a phase-gate methodology.
  • Experience in managing projects focused on solutions for people with diabetes a plus.
  • Knowledge and experience in the implementation of regulatory requirements for medical device development such as FDA’s Design Controls, ISO’s Risk Management and Medical Device standards, ISO Software Development standards (e.g., IEC 62304).

Tandem Diabetes Care designs and sells insulin pumps and related software for people with diabetes. Its flagship product is the t:slim X2 insulin pump, a subcutaneous device that delivers insulin and can work with other diabetes management devices through interoperable technology. A key feature is Basal-IQ, which uses continuous glucose monitoring data to predict low blood sugar and pause insulin delivery to prevent hypoglycemia. The company generates revenue from selling pumps and accessories like infusion sets and cartridges, as well as software updates and subscriptions for advanced management features, creating recurring income. Tandem differentiates itself with interoperable hardware and software that aim to simplify diabetes care and integrate with other devices, not just sell a single pump. Its goal is to improve diabetes management and quality of life by providing user-friendly, connected insulin delivery and management solutions for patients aged six and older.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy pay-as-you-go model doubles lifetime revenue per patient over four years.
  • Control-IQ+ FDA clearance for pregnancy expands type 1 market in 2026.
  • International expansion into Switzerland, Austria, UK lifts ASP by 20%.

What critics are saying

  • Infusion set shortages from sole supplier halt 20-30% shipments through Q3 2026.
  • Abbott Libre 3 closed-loop launches Q3 2026, diverting CGM users to tubeless.
  • Dexcom G7 standalone AID approval June 2026 obsoletes Tandem pump hardware.

What makes Tandem Diabetes Care unique

  • Control-IQ+ algorithm delivers +2 hours daily time-in-range versus competitors.
  • Cloud-based Tandem Source enables remote clinician workflows and payer insights.
  • Pipeline spans tubed t:slim X2, Mobi, and Sigi rechargeable patch pumps.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Tandem Diabetes Care who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

Remote Work Options

Hybrid Work Options

Employee Stock Purchase Plan

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Stock Titan
Mar 27th, 2026
Board asks shareholders to approve 3.26m-share increase; TNDM files proxy (TNDM).

Board asks shareholders to approve 3.26m-share increase; TNDM files proxy (TNDM). Filing Impact Filing Sentiment Rhea-AI Filing Summary. Tandem Diabetes Care is holding its 2026 Annual Meeting virtually on May 20, 2026 to vote on seven proposals, including election of nine directors, say-on-pay, an increase of 3,260,000 shares to the 2023 Long-Term Incentive Plan, certificate of incorporation amendments, and ratification of Ernst & Young LLP as auditor. The Record Date shows 68,504,233 shares outstanding as of March 23, 2026. The company reports 2025 business highlights including $1.015 billion in worldwide sales, over 126,000 pump shipments, and several product and regulatory milestones. Insights. Proxy seeks shareholder approval for governance and charter amendments alongside routine meeting items. The proxy presents six board-recommended proposals plus general meeting mechanics for the May 20, 2026 virtual meeting and discloses 68,504,233 shares outstanding as of March 23, 2026. Two charter amendments are proposed: a Section 141(k) removal amendment and an officer exculpation amendment tied to recent DGCL changes. Key dependencies include supermajority vote thresholds: the Section 141(k) and Officer Exculpation Amendments each require 66 2/3% approval. Subsequent filings will report vote results in a Form 8-K within four business days after the meeting. Board requests a 3,260,000-share increase to the 2023 equity plan and summarizes 2025 pay outcomes. The board proposes adding 3,260,000 shares to the 2023 Long-Term Incentive Plan and discloses current availability and activity metrics: 729,748 shares available as of March 16, 2026, a 2025 burn rate of 3.1%, and historical grants shown through March 16, 2026. The plan retains features such as minimum 12-month vesting, anti-repricing, clawback provisions, and director grant caps. Outcomes will hinge on shareholder approval; if not approved, the company states it may exhaust current reserves and be unable to grant customary awards thereafter. 03/27/2026 - 04:07 PM | / | / | / | / | / | / | / | / | / | Value of initial fixed $100 investment based on: | / | / | / | / | | Year | Summary Compensation Table Total for PEO(1) | / | CAP to PEO(1)(3) | / | Average Summary Compensation Table Total for Non-PEO NEOs(2) | / | Average CAP to Non-PEO NEOs(2)(3) | / | Total Shareholder Return(4) | / | Peer Group Total Shareholder Return TSR(4) | / | Net Income (loss) ($ in millions)(5) | / | Sales ($ in millions)(6) | | 2025 | $ | 6,858,503 | / | / | $ | 2,919,024 | / | / | $ | 1,970,448 | / | / | $ | 1,579,586 | / | / | $ | 22.97 | / | / | $ | 99.39 | / | / | $ | (204.7) | / | / | $ | 1,014.7 | / | | 2024 | $ | 8,526,238 | / | / | $ | 6,793,928 | / | / | $ | 1,945,074 | / | / | $ | 1,752,852 | / | / | $ | 60.43 | / | / | $ | 105.42 | / | / | $ | (96.0) | / | / | $ | 940.2 | / | | 2023 | $ | 4,651,603 | / | / | $ | 1,510,100 | / | / | $ | 1,497,536 | / | / | $ | 1,086,227 | / | / | $ | 49.62 | / | / | $ | 106.34 | / | / | $ | (222.6) | / | / | $ | 747.7 | / | | 2022 | $ | 6,378,515 | / | / | $ | (8,343,937) | / | / | $ | 1,746,125 | / | / | $ | (3,175,063) | / | / | $ | 75.41 | / | / | $ | 99.81 | / | / | $ | (94.6) | / | / | $ | 801.2 | / | | 2021 | $ | 5,739,882 | / | / | $ | 16,412,581 | / | / | $ | 1,616,639 | / | / | $ | 5,058,736 | / | / | $ | 252.51 | / | / | $ | 125.43 | / | / | $ | 15.6 | / | / | $ | 702.8 | / | 2) The non-PEO NEOs, for each year reported were as follows: - 2025: Elizabeth A. Gasser, Shannon Hansen, Mark D. Novara and Leigh A. Vosseller - 2024: Elizabeth A. Gasser, Jean-Claude Kyrillos, Susan M. Morrison, Mark D. Novara and Leigh A. Vosseller - 2023: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison, Mark D. Novara and Leigh A. Vosseller - 2022: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison and Leigh A. Vosseller - 2021: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison and Leigh A. Vosseller | Year | Executive(s) | / | Summary Compensation Table Total | / | Deduct: Stock Awards Granted in Year | / | Add: Year-End Fair Value of Unvested Equity Awards Granted in Year* | / | Add: Change in Year-End Fair Value of Unvested Equity Awards Granted in Prior Years | / | Add: Change in Year-End Fair Value of Equity Awards Granted in Prior Years Which Vested in Year | / | CAP | / | / | / | / | | 2025 | PEO | / | $ | 6,858,503 | / | / | $ | (5,367,796) | / | / | $ | 5,240,252 | / | / | $ | (2,611,510) | / | / | $ | (1,200,425) | / | / | $ | 2,919,024 | / | / | / | / | / | | Non-PEO NEOs | / | $ | 1,970,448 | / | / | $ | (1,226,792) | / | / | $ | 1,197,646 | / | / | $ | (166,600) | / | / | $ | (195,116) | / | / | $ | 1,579,586 | / | / | / | / | / | | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | * The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. 6) As required by Item 402(v) of Regulation S-K, we have determined that Sales is the Company-Selected Measure. * Annual sales for 2024, 2023 and 2022 include the effect of net sales recognized (deferred) of $30.2 million, ($25.1) million and ($3.5) million, respectively. This related to the accounting treatment associated with our Tandem Choice Program offering, which began in September 2022 and ended December 31, 2024, to provide a pathway to eligible t:slim X2 customers to ownership of our newest hardware platform, Tandem Mobi, for a fee when available. There was no comparative adjustment to pump sales in 2025. | Most Important Performance Measures Used to Link CAP to Company Performance: | | Sales | | Gross Margin | | Adjusted EBITDA Margin* | | New Product Launch Timing | | Customer Satisfaction | | / | We have not granted stock options, stock appreciation rights, or similar instruments with option-like features since 2022 and have no policies or practices to disclose pursuant to Item 402(x)(1) of Regulation S-K. Faq. What is Tandem Diabetes Care (TNDM) voting on at the 2026 annual meeting? The company asks shareholders to elect nine directors and vote on six additional items. These include say-on-pay, a 3,260,000 -share increase to the 2023 equity plan, two charter amendments, and ratification of Ernst & Young LLP as auditor. When and how will TNDM shareholders vote at the 2026 Annual Meeting? The virtual meeting is scheduled for May 20, 2026 at 3:00 p.m. Pacific time. Shareholders may vote by internet, telephone, mail, or during the webcast using the 16-digit control number or QR code provided in proxy materials. How many Tandem (TNDM) shares were outstanding for voting purposes? There were 68,504,233 shares of Common Stock outstanding as of the Record Date, March 23, 2026, and each share is entitled to one vote on meeting matters. What change to the 2023 Long-Term Incentive Plan is being proposed? The board proposes to increase the number of shares authorized under the 2023 Plan by 3,260,000 shares and describes governance features like a minimum 12-month vesting rule and a director grant cap of $750,000 per fiscal year. What voting thresholds apply to the charter amendments in the proxy for TNDM? Approval of the Section 141(k) Amendment and the Officer Exculpation Amendment each requires the affirmative vote of holders of at least 66 2/3% of outstanding common shares on the Record Date. What financial highlights from 2025 does Tandem disclose in the proxy? The proxy cites more than $1.015 billion in worldwide sales for 2025, record Q4 sales above $290 million, and over 126,000 annual pump shipments, along with product rollouts and an FDA clearance of Control-IQ+ for type 2 diabetes.

Yahoo Finance
Mar 15th, 2026
Tandem Diabetes expands Mobi insulin pump to Android, aiming for $1.1B in 2026 sales

Tandem Diabetes Care has expanded its Tandem Mobi automated insulin delivery system to compatible Android smartphones in the US, following FDA clearance in November 2025 and a limited release in December. The Android rollout broadens accessibility for Mobi users and strengthens the company's position in smartphone-based diabetes management. The expansion supports Tandem's investment thesis by widening accessibility and reinforcing ecosystem retention, though near-term pressures remain from flat renewal expectations and ongoing losses. Combined with October 2025's integration of t:slim X2 with Abbott's FreeStyle Libre 3 Plus CGM, the move demonstrates a broader connectivity strategy. Tandem's narrative projects $1.2 billion revenue and $14.4 million earnings by 2028, requiring 7.5% yearly revenue growth. The company's 2026 sales guidance stands at approximately $1.065 billion to $1.085 billion.

Yahoo Finance
Mar 2nd, 2026
Tandem hits record 58% margin, plans pharmacy shift and tubeless 'Toby' pump launch

Tandem Diabetes Care reported a record fourth-quarter gross margin of 58%, driven by pricing, rising Mobi volume and early pharmacy channel adoption. The company is transitioning US sales to a pharmacy pay-as-you-go model, creating a near-term $70–$80 million revenue headwind in 2026 but offering materially higher long-term reimbursement—approximately double over four years and four times monthly versus durable medical equipment. Tandem is expanding direct international sales in Switzerland, Austria and the UK, with an expected average selling price uplift of at least 20%. The company plans to submit its tubeless Mobi cartridge, nicknamed "Toby", to the FDA in Q2 for commercial rollout in the second half of the year. The device will be compatible with existing Mobi pumps.

MarketScreener
Feb 25th, 2026
Tandem Diabetes Care prices upsized $265M convertible notes offering due 2032

Tandem Diabetes Care has priced a $265 million private placement of convertible senior notes due 2032, up from the initially announced $200 million. The notes carry a 0.00% interest rate and will mature on 15 March 2032. The insulin delivery and diabetes technology company estimates net proceeds of approximately $256.7 million after deducting fees and expenses. Initial purchasers have an option to buy an additional $35 million in notes. The notes will be convertible at an initial rate of 27.0362 shares per $1,000 principal amount, equivalent to a conversion price of approximately $36.99 per share. This represents a 37.5% premium over Tandem's closing stock price of $26.90 on 24 February 2026. Tandem plans to use proceeds for capped call transactions costing $13.5 million and general corporate purposes including potential acquisitions and working capital. The offering is expected to close on 27 February 2026.

Yahoo Finance
Feb 23rd, 2026
Brown Capital Management sells Tandem Diabetes as revenue growth disappoints, profitability goals missed

Brown Capital Management has sold its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM), citing weaker-than-expected performance, according to its fourth quarter 2025 investor letter. The San Diego-based diabetes technology company, which develops insulin pumps with advanced automated delivery systems, faced increasing competition and greater market saturation amongst Type 1 diabetes patients. Revenue growth fell short of expectations whilst the company remained unprofitable throughout 2025. Tandem reported worldwide sales of $290 million in Q4 2025, representing 15% year-over-year growth. The stock closed at $24.57 per share on 20 February 2026, down 24.77% over the previous 52 weeks. The company has a market capitalisation of $1.666 billion, with 33 hedge funds holding positions at the end of Q4.